ArticleClinical pharmacology and therapeutics2026
Denosumab Offers Relatively Lower Initial Protection Against Osteoporotic Vertebral Fractures in Treatment-Naive Patients Compared With Zoledronate.
Article in Clinical pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discontinuing Long-Term Denosumab in Treating Fragile Bone: Why, for Whom, and How?Clinical pharmacology and therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the initial efficacy of denosumab (Dmab) and zoledronate (ZOL) in treatment-naive patients with osteoporosis. This cohort study, based on TriNetX data, evaluated the risks of fractures and mortality using Kaplan-Meier survival analyses, with hazard ratios (HRs) and 95% confidence intervals (CIs). Propensity-score matching generated 10,811 well-balanced patient pairs. Compared with initiation of annual ZOL, initiation of Dmab with the second dose administered within 7 months of the first injection (no or ≤ 1 month delay) was associated with higher risks of osteoporotic fractures (HR = 1.512, 95% CI = 1.277-1.790), vertebral fractures (HR = 1.609, 95% CI = 1.130-2.293), and lumbar fractures (HR = 2.225, 95% CI = 1.168-4.239). Fracture protection with Dmab declined markedly at 6-7 months but remained stable when two injections were administered within 6 months (no delay). Subgroup analyses showed higher risks of osteoporotic and vertebral fractures among Dmab users without diabetes, without prior steroid exposure, and with an estimated glomerular filtration rate ≥ 60 mL/min/1.73 m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.